JO
WINT

John Overdeck’s Windtree Therapeutics WINT Stock Holding History

John Overdeck’s Portfolio WINT Stock Details WINT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-289
Closed -$5.05K – 3520
2024
Q4 		$5.05K Buy
+289
New +$9.17K ﹤0.01% 3147

Other funds holding WINT

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

John Overdeck's WINT Position: Q1 2025 in Review

John Overdeck sold out of Windtree Therapeutics (WINT) in Q1 2025, closing a stake of 289 shares — an estimated $5.05K sold.

John Overdeck first reported a position in WINT in Q4 2024 and held it in 1 quarter. The position peaked at $5.05K in Q4 2024. 5 funds tracked by Wall St. Rank hold WINT as of Q1 2025.

  • John Overdeck reported no remaining Windtree Therapeutics position as of Q1 2025 after selling out during the quarter.
  • John Overdeck sold 289 Windtree Therapeutics shares in Q1 2025, an estimated $5.05K.
  • John Overdeck first reported a position in Windtree Therapeutics in Q4 2024 and held it in 1 quarter.
  • John Overdeck's Windtree Therapeutics position peaked at $5.05K in Q4 2024.
  • 5 funds tracked by Wall St. Rank held Windtree Therapeutics as of Q1 2025.

Based on Two Sigma Investments's 13F filing for Q1 2025, filed 15 May 2025.